Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trophos has received an award of EUR6m from the European Union (EU) to support MitoCare - an international, translational medicine project evaluating a novel cardioprotective compound.
Subscribe to our email newsletter
MitoCare will begin in January 2011 and will be conducted by a 16 partner consortium led by Trophos.
MitoCare will evaluate the safety and efficacy of TRO40303 in a Phase II proof-of-concept study to treat cardiac ischemia-reperfusion injury (IRI) in acute myocardial infarction (MI) patients.
The study will also develop knowledge of biomarkers and models of cardiac ischemia-reperfusion injury.
The study will involve acute MI patients with large myocardial infarct undergoing coronary angioplasty, who will be administered with TRO40303 as a single IV infusion prior to the reperfusion by angioplasty.
TRO40303 is the second of Trophos’ proprietary cholesterol oxime mitochondrial pore modulators, whose mechanism of action involves prevention of stress-induced mitochondrial permeability transition, a target implicated in cardiac reperfusion injury.